Appropriate sequence for afatinib and cisplatin combination improves anticancer activity in head and neck squamous cell carcinoma

Pharmacology, Toxicology and Pharmaceutical Science

• Head and Neck Squamous Cell Carcinoma 100%
• Cisplatin 100%
• Afatinib 100%
• Epidermal Growth Factor Receptor Kinase Inhibitor 75%
• Chemotherapy 50%
• DNA 50%
• Epidermal Growth Factor Receptor 50%
• Cell Death 50%
• Cell Cycle 50%
• Neoplasm 25%
• Tumor Resistance 25%
• Drug 25%
• Receptor 25%
• Pathogenesis 25%
• Apoptosis 25%
• Cytotoxicity 25%
• Tumor Growth 25%
• Prognosis 25%
• Head and Neck Cancer 25%
• Clinical Trial 25%
• Head and Neck Tumor 25%
• Gamma Urogastrone 25%